Market Cap | 1.37M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -254k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -28.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -31.00% |
Dividend | N/A | Price/Book | 1.43 | EPS next 5Y | - | 52W High Chg | -67.00% |
Recommedations | - | Quick Ratio | 11.48 | Shares Outstanding | 136.98M | 52W Low Chg | 138.00% |
Insider Own | 8.17% | ROA | -12.61% | Shares Float | - | Beta | - |
Inst Own | 0.02% | ROE | -25.06% | Shares Shorted/Prior | -/- | Price | 0.01 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 14,041 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 4,201 | Change | 0.00% |
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment. The company was founded in 2006 and is headquartered in Toronto, Canada.